GlassScriptPhysician profile
Megan E Schriner
NPI 1770888117
$8,139.34
in general payments reported to CMS, 2019-2025
39 companies · $990 in 2025
The $990 reported for 2025 was more than what 83% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $183 · 2022: $1,855 · 2023: $1,688 · 2024: $3,423 · 2025: $990.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,799 · Food and Beverage: $1,375 · Travel and Lodging: $1,192 · Honoraria: $700 · Education: $35.06.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,799.37 |
| Food and Beverage | $1,374.78 |
| Travel and Lodging | $1,192.43 |
| Honoraria | $700.00 |
| Education | $35.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $3,765.91 | 2022-2024 | Opdivo, Opdualag |
| G1 Therapeutics, INC. | $1,323.78 | 2022 | |
| Catalyst Pharmaceuticals, INC. | $776.84 | 2025 | |
| Janssen Scientific Affairs, LLC | $648.32 | 2023 | Erleada, Balversa, Darzalex |
| Exelixis INC. | $219.86 | 2022-2024 | Cabometyx |
| Abbvie INC. | $152.02 | 2022-2025 | |
| Puma Biotechnology, INC. | $128.48 | 2022 | |
| Janssen Biotech, INC. | $118.00 | 2021-2023 | Tecvayli, Darzalex |
| Genentech, INC. | $105.80 | 2024 | Tecentriq |
| Geron Corporation | $67.10 | 2025 | Rytelo |
| Karyopharm Therapeutics INC. | $62.75 | 2021-2024 | Xpovio |
| Merck Sharp & Dohme LLC | $59.20 | 2021-2022 | |
| Genentech USA, INC. | $58.13 | 2023 | Polivy, Lunsumio |
| Astrazeneca Pharmaceuticals LP | $56.96 | 2024-2025 | Imfinzi, Tagrisso |
| Stemline Therapeutics INC. | $55.87 | 2023 | Orserdu |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Megan Schriner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.